Market Place
Sourcing Support
Acadia Announces Health Canada Approval Of Daybue For Rett Syndrome
16 Oct 2024 //
BUSINESSWIRE
DAYBUE™ Long-Term Data For Rett Syndrome Published In Med
18 Jul 2024 //
BUSINESSWIRE
Acadia Presents DAYBUE™ Real-World Evidence In Rett Syndrome At IRSF Meeting
18 Jun 2024 //
BUSINESSWIRE
Acadia`s Trofinetide NDS For Rett Accepted, Priority Review
22 Apr 2024 //
BUSINESSWIRE
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study
08 Jun 2023 //
BUSINESSWIRE
Acadia Pharma Announces DAYBUE™ (trofinetide) is Now Available
17 Apr 2023 //
BUSINESSWIRE
Acadia Announces Trofinetide NDA has been Accepted for Filing & Review by USFDA
12 Sep 2022 //
BUSINESSWIRE
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Acadia Pharmaceuticals Submits NDA to the U.S. FDA for Trofinetide
18 Jul 2022 //
BUSINESSWIRE
Acadia touts late-stage win for its Rett syndrome drug
08 Dec 2021 //
ENDPTS
ACADIA Initiates Ph3 Pivotal Study of Trofinetide in Rett Syndrome
31 Oct 2019 //
BUSINESSWIRE
ACADIA`s Initiates Ph3 Pivotal Study of Trofinetide in Rett Syndrome
30 Oct 2019 //
BUSINESSWIRE
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome
28 Mar 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.